Process for the determination of lipoproteins in body fluids

Details Process for the determination of lipoproteins in body fluids Process for the determination of lipoproteins in body fluids

2011-04-19

2011-04-19

Wallenhorst, Maureen M (Department: 1777)

Chemistry: analytical and immunological testing

Lipids, triglycerides, cholesterol, or lipoproteins

C436S063000, C436S173000, C422S068100, C702S019000, C702S022000, C702S023000, C702S032000, C324S307000, C324S308000, C324S312000

Reexamination Certificate

active

07927878

ABSTRACT:
The invention describes a process for the determination of the concentration distribution and size distribution of lipoprotein classes in body fluids, e.g. blood. For this purpose, NMR spectra of a sample to be analysed are measured by magnetic field gradient intensities and temperatures under different diffusion-weighted measuring conditions selected according to different pulse programs (e.g. PFG-STE, PFG-LED etc) and consequently in a differentiated manner according to the relaxation times. The different effects of these measuring conditions on the intensity/line form of the NMR signals of the individual lipoprotein classes are determined and permit the determination of a concentration distribution/size distribution of the individual lipoprotein classes.

REFERENCES:
patent: 4933844 (1990-06-01), Otvos
patent: 5343389 (1994-08-01), Otvos
patent: 6576471 (2003-06-01), Otvos
patent: 6617167 (2003-09-01), Otvos et al.
patent: 6653140 (2003-11-01), Otvos
patent: 2003/0054559 (2003-03-01), Otvos et al.
patent: 2004/0142496 (2004-07-01), Nicholson et al.
patent: 2006/0183234 (2006-08-01), Otvos
patent: 0 361 214 (1994-07-01), None
patent: WO 93/03450 (1993-02-01), None
patent: WO 03/012416 (2003-02-01), None
Analytica, Munchen 11.-14.05 2004, Halle A 5, Stand A5.251-A5.350 bzw.A5.261-A5.360,Beteiligunng der Bayerischen Universitäten an der Analytica 2004, Exponate der Analytica 2002 pp. 1-5; Bayern Innovativ-Analytica 2004 pp. 1-3.
Kapital 3, Kernresonanz-Spektren, Hesse M. et al, vol. 4, p. 132.
Clin. Chem. 37/3, 377-386 (1991),Quantification of Plasma Lipoproteins by Proton Nuclear Magnetic Resonance Spectroscopy, J.D. Otvos, E.J. Jeyarajah and D.W. Bennett.
Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women, Gavin J. Blake, MB, MSc, MRCPI; James D. Otvos, PhD; Nader Rifai, PhD; Paul M. Ridker, MD, MPH, pp. 14:11 Nov. 29, 2006, pp. 2-9, 2002.
Nuclear Magnetic resonance chromatography: applications of pulse field gradient diffusion NMR to mixture analysis and ligand-receptor interactions, John S. Gounarides, Aidi Chen, Michael J. Shapiro, Journal of Chromatography B. 725 (1999) 79-90.
Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health Study, Lewis Kuller, Alice Arnold, Russell Tracy, James Otvos, Greg Burke, Bruce Psaty, David Siscovick, David S. Freedman, Richard Kronmal, Arterioscler Thromb Vasc Biol., pp. 1175-1180, Jul. 2002.
Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial, James D. Otvosa.b, Irina Shalaurovaa.b, David S. Freedmanc, Robert S. Rosensondd.*, Atherosclerosis 160 (2002) 41, 48, Department of Biochemistry, North Carolina State University, Raleigh, NC, Jul. 14, 2000; revised form Apr. 6, 2001; accepted Apr. 30, 2001.
Relations of Lipoprotein Subclass Levels and Low-Density Lipoprotein Size to Progression of Coronary Artery Disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries(PLAC-1)Trial, Robert S. Rosenson, MD, James D. Otvos, PhD, and David S. Freedman, PhD., 2002 by Excerpta Medico, Inc., The American Journal of Cardiology vol. 90 Jul. 15, 2002, pp. 89-94.
Analysis of Biofluids and Chemical Mixtures in Non-deuterated Solvents with1H Diffusion-Weighted PFG Phase-Sensitive Double-Quantum NMR Spectroscopy, Claudio Daivit and Jean Marc Böhlen, NMR in Biomedicine, vol. 10, 285-291 (1997), XP009052972.
Proton magnetic resonance spectroscopy of fractionated plasma lipoproteins and reconstituted plasma from healthy subjects and patients with cancer, T. Emngan, K.S. Bjerve, A.L. H0E & J. Krane, Departments of Oncology and Radiotherapy and Clinical Chemistry, University Hospital of Trondheim, and The Center for Nuclear Magnetic Resonance, SINTEF, UNIMED, Trondheim, Norway, pp. 393-408, XP009052938, 1992.
750 MHz1H-NMR spectroscopy of human blood plasma, P.J.D. Foxall, M. Spraul, R.D. Farrant, L.C. Lindon, G.H. Neild and J.K. Nicholson, Journal of Pharmaceutical & Biomedical Analysis, vol. 11, No. ⅘, pp. 267-276, 1993, XP-002342275.
750 MHz1H and1H-13C NMR Spectroscopy of Human Blood Plasma, Jeremy K. Nicholson and Peta J.D. Foxall, Departmetn of Chemistry, Birkbeck College, University of London, Gordon House, 29 Gordon Square, London WC1H OPP, U.K., Analytical Chemistry, vol. 67, No. 5, Mar. 1, 1995, pp. 793-811.
Biomolecular NMR Spectroscopy, 2—Methods for spectral assignment—multidimensional NMR, Jeremy N.S. Evans 1995, Oxford University Press, New York, pp. 55-98.
Fourier Transform Pulsed-Gradient Spin-Echo Studies of Molecular Diffusion, Peter Stilbs, Institute of Physical Chemistry, Uppaala University, Swedon, Progress in NMR Spectroscopy, vol. 19, pp. 1-45, 1987.

Affiliated with

Also associated with

Rating

Process for the determination of lipoproteins in body fluids does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for the determination of lipoproteins in body fluids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the determination of lipoproteins in body fluids will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2623653